In an effort to develop a method for better local control of advanced ovarian cancers, we have established a peritoneal tumor model of ovarian cancer in the nude mouse and applied intraperitoneal gene therapy with the recombinant adenoviral-mediated wild-type p53 tumor suppressor gene (Avp53). The results indicate that: (a) the recombinant adenoviral vector system effectively infected the tumor and normal cells in the peritoneal cavity; and (b) Avp53 treatment effectively suppressed the growth of peritoneal tumors and prolonged the survival of the treated group, especially when the tumor burden was less. These results suggest that intraperitoneal gene therapy using Avp53 is potentially useful as an adjuvant therapeutic modality in human ovarian cancer.
O varian cancer is the most common cause of death among gynecological cancers. The incidence of this type of cancer has increased, and mortality from ovarian cancer accounts for 12% of gynecological malignancies in Korea. 1 On a worldwide basis, the total number of cases was estimated to be ϳ140,000 in 1980, representing Ͼ4% of all cancers in women. 2 The result of current therapy for ovarian cancer is disappointing. Ovarian cancer is often asymptomatic until it has been disseminated; Ͼ55% of cases, at the time of diagnosis, show spreads of the tumor beyond the ovaries, with peritoneal implants outside of the pelvis (peritoneal tumor). Despite intensive therapy using surgery, radiation, and chemotherapy, overall 5-year survival in stage III is Ͻ15%. 3 Fortunately, however, the distant extraperitoneal metastasis develops later in its clinical course of ovarian cancer. Moreover, even in the patients with distant metastasis, local cytoreductive treatment is considered to be a rational approach, because systemic chemotherapy has been shown to exert a better control of the disease when the tumor burden is less. Therefore, the effective control of the peritoneal tumor can give patients a chance to survive.
Recently, based on the fact that cancer is a disease generated through a process of genetic alterations, the potential usefulness of gene therapy has begun to be investigated. Gene therapy with the wild-type (wt) p53 tumor suppressor gene is one possibility. wt p53 transfer has been shown to suppress cell transformation and induce apoptosis in several tumors in which the p53 gene is deleted or mutated. 4 -7 Because p53 mutations are among the most frequently observed genetic alterations in advanced ovarian cancer, 8, 9 p53-based gene therapy can be an appropriate approach to treat this type of cancer.
In this study, we established an animal model in which peritoneal tumors developed and progressed as time passed. After confirming the tumoricidal effect of the transfer of wt p53 using an adenoviral vector (Avp53) on tested ovarian cancer cells by in vitro study, we have applied intraperitoneal (i.p.) Avp53 to the animals with peritoneal tumors. The results indicate that i.p. p53 gene therapy can significantly suppress the growth of peritoneal tumors and extend the survival of tested animals.
MATERIALS AND METHODS

Cell lines and culture conditions
The ovarian cancer cell lines Ov-Ca-2774 (2774) and SKOV3 were purchased from the American Type Culture Collection (Manassas, Va) and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine sera. These cell lines have a different status of endogenous p53; SKOV3 is null for p53 because of a nonsense mutation and chromosome rearrangement; 2774 has mutant p53 at codon 273 (Arg3 His; CGT3 CAT). The human embryonic kidney cell line 293 was maintained in modified Eagle's medium supplemented with 10% fetal bovine sera.
Construction of adenovirus expressing wt p53
The method of construction of the adenovirus containing wt p53 cDNA (Avp53) was described previously. 10 Briefly, the 1.8-kilobase XbaI fragment of wt human p53 cDNA was end-modified by attaching BamHI linkers and inserted at the BamHI site in the multiple cloning region of p⌬ACMVp(A) to give rise to p⌬ACMVp53. p⌬ACMVp53 and an adenovirus vector pJM17 11 were used to cotransfect a packaging cell line, 293, by the calcium phosphate method. A replication-competent virus (RCV)-negative clone was further propagated in 293 cells grown in 40 150-mm dishes and purified through two rounds of CsCl density gradient centrifugation. The titers of the virus stocks were determined by plaque assay on lawns of 293 cells. AdRSV-␤-gal, a ␤-galactosidase (␤-gal)-expressing adenovirus, was kindly provided by Wei Wei Zhang (Baxter, Deerfield, Ill).
Avp53 infection, immunoblotting analysis, and measurement of in vitro cytopathic effect
To evaluate the expression of p53 and p21WAF1/CIP1 in the ovarian cancer cell lines SKOV3 and 2774, cells treated with 20 multiplicities of infection of Avp53 or AdRSV-␤-gal were processed to immunoblotting analysis. Protein bands were probed with anti-p53 antibody (BP-1; Novocastra, Newcastle on Tyne, U.K.) or anti-p21WAF1/CIP1 polyclonal antibody (PharMingen, San Diego, Calif) and labeled with horseradish peroxidase-conjugated anti-mouse antibody (Amersham, Buckinghamshire, U.K.).
The effect of Avp53 treatment on cell growth was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay. Approximately 3 ϫ 10 3 cells were seeded in each well of 96-well plates 30 hours before being treated with incremental doses of RCV-free Avp53 or AdRSV-␤-gal. Thereafter, at 48 hours, the absorbance at 540 nm (with reference at 650 nm) was measured.
Development of peritoneal tumor model of human ovarian cancer
Surgical procedures and techniques for the development of the animal model were performed under institutional guidelines and were approved by the Institutional Committee on the Use and Care of Animals. Five-week-old female nude mice were used for the experiment and housed in the biocontainment facility in the Laboratory for Animal Medicine throughout the experimental period. The animals were anesthetized with intramuscular ketamine (0.08 mg/g), followed by i.p. xylazine (0.009 mg/g). All surgical instruments were sterilized, and the mice were prepped and draped before the operation. Aseptic conditions were maintained throughout the procedure, which was performed under a laminar flow hood. Following the establishment of satisfactory anesthesia, the abdomen was entered through a small abdominal incision. Tumor cells (2774 human ovarian cancer cell line, 1 ϫ 10 6 cells) in a volume of 50 L of phosphate-buffered saline (PBS) were introduced into the peritoneal cavity, and the incision was closed with a continuous suture. All animals tolerated the procedure well. The animals were allowed to recover, kept in a specialized shielding area, and observed daily until sacrificed.
From 1 week after the operation, five animals per week were sacrificed for 4 weeks. A thorough evaluation of all of the organs was performed by autopsy and pathological confirmation. Tumor formation was recorded as follows: (a) the number of peritoneal tumor nodules Ͻ3 mm in diameter, (b) the number of peritoneal tumor nodules Ͼ3 mm in diameter, (c) the presence of hepatic metastasis, (d) the presence of malignant ascitis, and (e) the presence of lung metastasis.
In vivo gene-marking study
To demonstrate the localization of adenovirus in vivo, animals were treated with an i.p. injection of AdRSV-␤-gal at 14 days after the i.p. inoculation of tumor cells. Animals were sacrificed at 7 days after treatment, and peritoneum, mesenteries, liver, lung, kidney, and leg muscle were harvested. Representative samples of solid organs were dissected into 0.5-cm sections and immersion-fixed for 1 hour using 2% glutaraldehyde in 100 mM piperazine-N,NЈ-bis(2-ethanesulfonic acid) (PIPES) (pH 6.9). Tissue samples were then rinsed twice in PBS/2 mM MgCl 2 and stained for 4 hours with 5-bromo-4-chloro-3-indolyl ␤-D-galactoside (X-Gal) solution as described previously. 12 Samples reacted with X-Gal were also postfixed in 4% glutaraldehyde, cryopreserved using 20% sucrose, and frozen in OCT compound (Miles, Elkhart, Ind). Sections were placed on the slides, counterstained lightly with hematoxylin, and examined by light microscopy.
Effect of i.p. Avp53 on peritoneal tumor implants
To determine the effect of Avp53 on peritoneal tumors, mice with peritoneal tumors were generated by the same method described above regarding the development of a peritoneal tumor model of human ovarian cancer. Subsequently, 500 L of PBS containing Avp53 (1 ϫ 10 9 plaque-forming units (PFU)), the same amount of PBS containing AdRSV-␤-gal (1 ϫ 10 9 PFU), or the same amount of PBS alone was introduced into the peritoneal cavity. The surgical procedures and the techniques for the administration of recombinant adenoviral vectors were performed under institutional guidelines and were approved by the Institutional Committee on the Use and Care of Animals and Recombinant DNA Research.
Animals were observed daily until death or sacrifice; necropsies, including pathological confirmation, were performed. Findings were recorded as the method used in the development of the animal model. Survival differences among the groups were compared; their statistical significance was analyzed using the generalized log-rank test.
RESULTS
Production of recombinant adenovirus expressing functional p53 protein
Multiple virus clones were isolated from 293 cells cotransfected with p⌬ACMVp53 and pJM17. Their quality as vectors for the study of the cytopathic effects of p53 was checked by applying two criteria: (a) Avp53 should express functionally active p53 protein in the transduced cells, and (b) Avp53 should be free of RCV contamination. We selected the RCV-free viral clone and tested the expression of p53 and p21WAF1/CIP1 in the ovarian cancer cell lines SKOV3 and 2774. At 48 hours postinfection, induction of p53 and p21WAF1/CIP1 in tested cell lines was apparent (Fig 1) .
Cytopathic effect of Avp53 infection on ovarian cancer cell lines
Cell monolayers of the 2774 cell line were infected with increasing concentrations of Avp53 or AdRSV-␤-gal. The control AdRSV-␤-gal had no effect on cell growth at any tested PFU/cell. In contrast, Avp53 reduced cell growth rates significantly (Fig 2A) . The reduction of cell numbers was accompanied by concomitant features of apoptotic cell death such as membrane blebbing and cell fragmentation, which was confirmed by ApopTag assay (Fig 2B) . The result indicates that Avp53 treatment has a cytocidal effect on the 2774 cell line in a dosedependent manner.
Development of peritoneal tumor model of human ovarian cancer A total of 20 mice were used to develop a peritoneal tumor model of ovarian cancer. From 1 week after inoculation, five mice per week were sacrificed and a complete evaluation of tumor growth was undertaken. At 1 week postinoculation, fine tumor nodules (1-2 mm in diameter) were noticed in all five animals (100%). In two of five mice, some bigger nodules (4 -5 mm in diameter) were also seen. At the end of 2 weeks, every animal had multiple and sizable tumor nodules (Ͼ3 mm in diameter), without any evidence of hepatic metastasis. At the end of 3 weeks, the tumor nodules were more evident and bigger (Յ1 cm in diameter). Moreover, in two of five mice, hepatic metastatic nodules were present. At the end of the 4th week, one of five animals had a tense abdomen and died spontaneously. Necropsy showed massive ascitis, abundant peritoneal nodules, left renal infarct due to the encroachment of tumor to the left renal artery, and extensive hepatic metastasis. The remaining four animals also showed abundant tumor nodules, mild ascitis, and small nodules of liver metastasis. The findings are listed in Table 1 .
In vivo gene-marking study To demonstrate the localization of adenovirus in vivo, animals were treated with an i.p. injection of AdRSV-␤-gal (1 ϫ 10 10 in 500 L of PBS) at 14 days after an i.p. inoculation of tumor cells. Animals were sacrificed at 1 week after treatment, and tissue samples were prepared for evaluation. X-Gal staining of sections obtained from the peritoneum showed Escherichia coli lacZ (lacZ) activity on the surface of the tumor nodules as well as on the normal tissues of the peritoneal wall (Fig 3A) . Because of the technical difficulty in the preparation of the small tumor nodules on the peritoneal wall, the depth of viral infection into the tumor nodule could not be identified clearly. However, sections of the liver showed that X-Gal-stained cells consisted of ϳ90% of total cells in the whole organ regardless of the anatomical lobes (Fig 3B) . Samples of the lung showed some, but markedly decreased, activity (10 -20%) in the overall areas of the sections. Similar findings were observed in the samples from the medulla of the kidney and leg muscles. With a decrease in the dose of the AdRSV-␤-gal treatment (use of a one-tenth (1 ϫ 10 9 in 500 L of PBS), one-hundredth (1 ϫ 10 8 ), and one-thousandth dose (1 ϫ 10 7 )), the number of stained cells in the liver was gradually decreased (Fig 4) .
Effect of i.p. Avp53 on peritoneal tumors
At 1 week of tumor inoculation, 500 L of PBS containing Avp53 (1 ϫ 10 9 PFU, p53 treatment group, n ϭ 10), the same amount of PBS containing AdRSV-␤-gal (1 ϫ 10 9 PFU, ␤-gal treatment group, n ϭ 10), or the same amount of PBS alone (no treatment group, n ϭ 10) was introduced into the peritoneal cavity. The same (but repeated) surgical technique was used as tumor inoculation into the peritoneal cavity. Animals were evaluated daily, and the development of a palpable abdominal mass or ascitis, body weight, and a change of activity were recorded. Some of the animals in the ␤-gal treatment group and the no treatment group showed decreased activity since day 25 of the treatment. Before day 35, all mice in the ␤-gal treatment group (10/10) and nine mice in the no treatment group (9/10) died spontaneously, whereas only one mouse in the p53 treatment group (1/10) died spontaneously (Fig 5) . Necropsy showed extensive tumor growth in the peritoneal cavity and hepatic metastasis with ascitis. Because the survival rate on day 35 was so markedly different and statistically significant (P Ͻ .01), we did not retain the survivors until death; rather, remaining mice were sacrificed on day 42 to evaluate the effect of Avp53 treatment on the preexisting peritoneal tumor. Six of nine surviving mice in the p53 treatment group revealed no tumor in the peritoneal cavity. In the remaining three animals, small peritoneal nodules were identified, and in one animal, a small hepatic metastatic nodule was also identified. This experiment clearly indicates that i.p. Avp53 treatment effectively suppressed the growth of peritoneal tumors and prolonged the survival of treated victims.
To evaluate the effect of Avp53 on the more progressed peritoneal tumor implants, we treated the animals at different times. Because we evaluated the i.p. tumor growth on a weekly basis, the timing of Avp53 treatment was set up the same way, as follows: Avp53 treatment at 2 weeks after tumor inoculation (2-week p53 treatment group, n ϭ 5), PBS injection without Avp53 at 2 weeks after tumor inoculation (2-week no treatment group, n ϭ 5), Avp53 treatment at 3 weeks after tumor inoculation (3-week p53 treatment group, n ϭ 5), and PBS injection without Avp53 at 3 weeks after tumor inoculation (3-week no treatment group, n ϭ 5). Animals were evaluated daily for 21 days and then sacrificed for an evaluation of tumor growth in the peritoneal cavity.
Every animal in the 2-week p53 treatment group survived until sacrifice at day 21. Autopsy revealed that three of five had no tumor; the remaining two mice had sizable tumor nodules near the incision line. In contrast, in the control group (2-week no treatment group), one of five mice died on the day 19 due to massive hepatic metastasis; all other mice also showed extensive tumor nodules in the peritoneal cavity as well as in the liver. When we applied the treatment at 3 weeks after tumor inoculation, a less prominent difference was noticed between treatment and control groups. Every treated mouse (3-week p53 treatment group) survived, but two of five mice in the control group (3-week no treatment group) died spontaneously. However, autopsy revealed that all mice, regardless of treatment, had variable degree of tumor nodules in the peritoneal cavities as well as on the surface of the liver. Data from the experiments are summarized in Table 2 .
DISCUSSION
When cancer spreads in the peritoneal cavity, a complete eradication of tumor cells by surgery can rarely be accomplished. Although adjuvant therapies including irradiation and/or chemotherapy have been used after surgery, the results are unsatisfactory; most of the patients die because of the residual cancer. To control local tumor spread effectively, based on the fact that cancer is a disease generated through a process of genetic alterations, several new strategies of local gene therapy are being developed. Two different approaches seem to be attractive in advanced ovarian cancer. The first approach is suicidal gene therapy that uses recombinant virus bearing a herpes simplex virus thymidine kinase (HSV-TK) gene. 13, 14 The strategy is to transduce tumor cells and, by virtue of HSV-TK expression, sensi- tize them to the antiherpetic drug ganciclovir, which is metabolized to large amounts of the cytotoxic product by HSV-TK but not by mammalian host TK. This approach has proven to be quite attractive. However, the limited applicability may be a concern in ovarian cancer, as described by Smythe et al, 15 who observed that ovarian cancer cells were quite resistant compared with mesothelioma or non-small cell lung cancer cells. The other approach is replacement gene therapy using recombinant viral-mediated transfer of wt p53 gene. We prefer this method, because the incidence of abnormalities of p53 is high in ovarian cancer, which gives the possibility of a high number of beneficial candidates.
In this study, our concern was whether the p53-based gene therapy would be practically useful in ovarian cancer patients with peritoneal tumors. According to the study by McGarrity et al, 3 Ͼ80% (4321/5254) of patients presented with local disease without systemic metastasis; 48% of patients (2074/4321) had peritoneal implants outside the pelvis (stage III). Moreover, even in patients with a earlier stage of disease, factors of local spread (for example, tumor rupture, surface excrescence, or the presence of ascitis) are seen frequently. The animal model we developed showed widespread peritoneal tumor implants in the peritoneal cavity, which can speak for the actual problem in patients. As time passed, implanted tumor nodules grew and metastasized as the natural tumor. The life span of a mouse with a peritoneal tumor was ϳ4 -5 weeks; this duration is optimal to evaluate the effectiveness of treatment.
With an in vivo gene-marking study, we demonstrated that i.p. delivered adenoviral vector was effectively transduced into peritoneal tumor nodules. We could not define how deeply the introduced virus infected the cells in the tumor nodule. However, we identified that the vector was efficiently absorbed into the liver. If the virus infected the liver cells by direct contact, only the surface of liver should have been stained. Thus, it seems that the virus should effectively infect the tumor and normal cells in the peritoneal cavity and then be transferred to the liver through the portal vein. The viral vectors, after infecting the hepatocytes, reached the heart and were rendered to the pulmonary and systemic circulation. The infection rate was directly related to the dose of the vector. This result suggests that the systemic side effect would occur if there were replication-competent adenovirus, although no RCV was identified in our vector system and the use of replication-incompetent adenoviral vectors has been regarded as safe. 16 The effect of the i.p. Avp53 was outstanding as described in Results. The 5-week survival rate was improved to 95% after Avp53 treatment, compared with only 10% without Avp53 treatment. Moreover, more than half of the animals showed a complete eradication of peritoneal tumors after Avp53 treatment. This result indicates that the i.p. p53 gene therapy suppressed the growth of the peritoneal tumors. In addition, this therapy may have eradicated the preexisting tumor nodules. This tumor-suppressive effect was still observable when we applied Avp53 to the animals at 2 weeks postinoculation. The animals with treatment survived and were free from hepatic metastasis. However, when Avp53 treatment was applied to the mice with hepatic metastasis (3 weeks postinoculation), the effect was not so prominent. Multiple sizable nodules in the peritoneal cavity and hepatic metastases were found even in the Avp53-treated mice. This finding may be related to the limited efficiency of the vector system to the deeply seated tumor cells. However, when we consider the use of Avp53 as an adjuvant therapy after cytoreductive surgery, it may not be a critical limitation for the application. In ovarian cancer, there has been good evidence of an inverse relationship between residual tumor diameter and survival. [17] [18] [19] "Optimal debulking" for systemic chemotherapy has come to denote residual disease of Յ1.5-2.0 cm in diameter. 18 Therefore, application of Avp53 after assiduous resection of the peritoneal tumor may achieve complete eradication of the tumor in the peritoneal cavity and significantly improve survival.
Aside from this experiment, there has been no work as of yet to evaluate the role of the local gene therapy to highly advanced tumors. When these observations are taken together, this experiment using i.p. gene therapy strategy provides promising evidence to continue the evaluation of Avp53 gene therapy in advanced ovarian cancer. More studies are also needed to determine the possible problem of immune response and the safety of adenoviral-mediated gene therapy. These studies may *Peritoneal tumors were generated with 1 ϫ 10 6 2774 cells, and the mice were treated with or without Avp53 on day 14 (2-week, Avp53 treatment, 2-week, no treatment) and on day 21 (3-week, Avp53 treatment, 3-week, no treatment). Animals were evaluated daily and sacrificed for autopsy on day 21 after treatment.
eventually prove to be useful for future gene therapy in human ovarian cancer patients.
